Next earnings date: 6 Aug 2025
Veru Inc. – NASDAQ:VERU
Veru stock price today
$3.35
+2.67
+395.71%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
Veru stock price monthly change
-28.62%
month
Veru stock price quarterly change
-28.62%
quarter
Veru stock price yearly change
-4.33%
year
Veru key metrics
Market Cap | 93.39M |
Enterprise value | 39.38M |
P/E | -0.75 |
EV/Sales | 1.42 |
EV/EBITDA | -0.35 |
Price/Sales | 2.93 |
Price/Book | 1.65 |
PEG ratio | N/A |
EPS | -0.73 |
Revenue | 17.92M |
EBITDA | -65.43M |
Income | -66.27M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -412.01% |
Oper. margin | -410.61% |
Gross margin | 70.15% |
EBIT margin | -410.61% |
EBITDA margin | -365.09% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVeru stock price history
Veru stock forecast
Veru financial statements
| Mar 2023 | 6.58M | -38.79M | -589.02% |
|---|---|---|---|
| Jun 2023 | 3.34M | 6.31M | 188.98% |
| Sep 2023 | 3.86M | -23.76M | -615.43% |
| Mar 2024 | 4.13M | -10.02M | -242.45% |
| Sep 2023 | 3.86M | -23.76M | -615.43% |
|---|---|---|---|
| Mar 2024 | 4.13M | -10.02M | -242.45% |
| Sep 2025 | 7.5M | -12.07M | -160.96% |
| Oct 2025 | 2.7M | -11.71M | -433.72% |
Analysts Price target
Financials & Ratios estimates
| 2024-08-08 | -0.06 | -0.07 |
|---|
| Mar 2023 | 70253570 | 53.53M | 76.21% |
|---|---|---|---|
| Jun 2023 | 75195414 | 40.80M | 54.27% |
| Sep 2023 | 50595925 | 32.81M | 64.85% |
| Mar 2024 | 71800359 | 26.59M | 37.03% |
| Mar 2023 | -25.55M | -141.58K | 2.26M |
|---|---|---|---|
| Jun 2023 | -18.43M | 5.97M | 5.17M |
| Sep 2023 | -9.49M | 787.12K | 2.11M |
| Mar 2024 | -5.65M | -40.65K | -150.32K |
Veru alternative data
| Aug 2023 | 233 |
|---|---|
| Sep 2023 | 233 |
| Oct 2023 | 233 |
| Nov 2023 | 233 |
| Dec 2023 | 233 |
| Jan 2024 | 189 |
| Feb 2024 | 189 |
| Mar 2024 | 189 |
| Apr 2024 | 189 |
| May 2024 | 189 |
| Jun 2024 | 189 |
| Jul 2024 | 189 |
Veru other data
10.28%
-47.95%
of VERU is owned by hedge funds
66
-63
8.27M
-38.37M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 6711 | 171875 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | STEINER MITCHELL SHUSTER director, officer: President an.. | Common Stock | 28,066 | $1.32 | $36,991 | ||
Sale | STEINER MITCHELL SHUSTER director, officer: President an.. | Common Stock | 59,788 | $1.41 | $84,122 | ||
Purchase | FISCH HARRY director, officer.. | Common Stock | 6,711 | $1.49 | $9,999 | ||
Sale | STEINER MITCHELL SHUSTER director, officer: President an.. | Common Stock | 84,021 | $1.5 | $125,779 | ||
Option | EISENBERGER MARIO director | Common Stock | 45,000 | $1.2 | $54,000 | ||
Option | EISENBERGER MARIO director | Common Stock Option | 45,000 | $1.89 | $85,050 | ||
Sale | EISENBERGER MARIO director | Common Stock | 100,000 | $20.04 | $2,003,600 | ||
Option | EISENBERGER MARIO director | Common Stock | 45,000 | $1.89 | $85,050 | ||
Option | EISENBERGER MARIO director | Common Stock | 5,000 | $2.08 | $10,400 | ||
Option | EISENBERGER MARIO director | Common Stock | 5,000 | $1.5 | $7,500 |
| Patent |
|---|
Application Filling date: 11 Feb 2022 Issue date: 18 Aug 2022 |
Application Filling date: 5 Apr 2021 Issue date: 7 Oct 2021 |
Application Filling date: 21 May 2020 Issue date: 10 Sep 2020 |
Application Filling date: 15 May 2019 Issue date: 26 Dec 2019 |
| Quarter | Transcript |
|---|---|
| Q2 2024 8 May 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 8 Feb 2024 | Q1 2024 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 9 Feb 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Mitchell S. Steiner F.A.C.S., M.D., F.A.C.S (1961) Chairman, Pres & Chief Executive Officer | $874,600 |
| Dr. K. Gary Barnette Ph.D. (1968) Chief Scientific Officer | $507,010 |
| Dr. Harry Fisch (1959) Vice Chairman & Chief Corporation Officer | $465,020 |
| Ms. Michele Greco (1959) Chief Financial Officer & Chief Admin. Officer | $443,720 |
Veru: Great Potential Despite FDA Rejection Of Sabizabulin EUA
Veru Inc.: Q1 Revenues Fall Short And Uncertainty Looms, Making It Risky
Veru: A Good Combination Of A Stable Business And Growth Opportunities
Veru Inc.: A Very Complicated Tale
Veru: The Signs Seem To Point To An EUA For Sabizabulin
Veru: On Right Track For FDA EUA Submission
Veru Inc. Still Has Serious Growth To Realize
Veru: Where Big Pharma Failed To Tread
Veru Inc.: Women's Health, COVID Trial, Oncology Pipeline - 3 Opportunities For The Price Of 1
-
What's the price of Veru stock today?
One share of Veru stock can currently be purchased for approximately $3.35.
-
When is Veru's next earnings date?
Veru Inc. is estimated to report earnings on Wednesday, 6 Aug 2025.
-
Does Veru pay dividends?
No, Veru does not pay dividends.
-
How much money does Veru make?
Veru has a market capitalization of 93.39M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.62% to 16.89M US dollars. Veru made a loss 37.8M US dollars in net income (profit) last year or -$0.07 on an earnings per share basis.
-
What is Veru's stock symbol?
Veru Inc. is traded on the NASDAQ under the ticker symbol "VERU".
-
What is Veru's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Veru?
Shares of Veru can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Veru's key executives?
Veru's management team includes the following people:
- Dr. Mitchell S. Steiner F.A.C.S., M.D., F.A.C.S Chairman, Pres & Chief Executive Officer(age: 64, pay: $874,600)
- Dr. K. Gary Barnette Ph.D. Chief Scientific Officer(age: 57, pay: $507,010)
- Dr. Harry Fisch Vice Chairman & Chief Corporation Officer(age: 66, pay: $465,020)
- Ms. Michele Greco Chief Financial Officer & Chief Admin. Officer(age: 66, pay: $443,720)
-
How many employees does Veru have?
As Jul 2024, Veru employs 189 workers.
-
When Veru went public?
Veru Inc. is publicly traded company for more then 26 years since IPO on 11 Feb 1999.
-
What is Veru's official website?
The official website for Veru is verupharma.com.
-
Where are Veru's headquarters?
Veru is headquartered at 48 NW 25th Street, Miami, FL.
-
How can i contact Veru?
Veru's mailing address is 48 NW 25th Street, Miami, FL and company can be reached via phone at +30 55096897.
Veru company profile:
Veru Inc.
verupharma.comExchange:
NASDAQ
Full time employees:
189
Industry:
Biotechnology
Sector:
Healthcare
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
48 NW 25th Street
Miami, FL 33127
Miami, FL 33127
CIK: 0000863894
ISIN: US92536C1036
CUSIP: 92536C103
